Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.

This review discusses various chromatographic methods for analyzing finasteride in biological fluids and provides no clinical findings, focusing on detection techniques for different concentration levels.

This review discusses the advancements in understanding and treating androgenetic alopecia and alopecia areata but reports no clinical findings; the authors emphasize the need for further research on molecular control mechanisms.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

This review discusses the use of finasteride and alpha antagonists for symptomatic benign prostatic hypertrophy and suggests current studies are evaluating combination therapies as potential non-surgical alternatives.

This review discusses three aspects of cell fate specification across Metazoa and reports no new experimental results, highlighting the formation of nematode equivalence groups, evolution of echinoderm skeletogenic mesoderm, and adult cell fate regulation.

Fermentation of Finasteride with Ocimum sanctum L. creates new metabolite that inhibits tyrosinase.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

This study observed that finasteride, especially when combined with electrolysis, effectively reduced hair growth in women with hirsutism over six months.

This study identified novel compounds as selective inhibitors of the type 1 isoenzyme of 5α-reductase, displaying promising potential for treating DHT-dependent disorders such as acne and androgenic alopecia.

This study found that the metabolic profile of finasteride in pigs closely matches that of humans, supporting the use of pigs for studying human drug metabolism.

This review discusses current therapeutic targets and treatments for androgenic alopecia but reports no clinical results; the authors highlight the challenge of developing multi-target drugs for effective treatment.

This study found that octahydrobenzo[c]quinolizin-3-one derivatives, particularly compound 3, were potent and selective inhibitors of the enzyme 5α-reductase type 1.

This article reviews the use of finasteride for treating male pattern hair loss, highlighting its mechanism of action in reducing DHT and noting its safety profile with some common adverse effects.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

Finasteride remains stable for two years with proper storage.

New, cheaper method measures finasteride in tablets accurately and quickly.

This study found that certain curcumin analogs derived from natural plant sources exhibit anti-androgen activity by inhibiting steroid 5-alpha reductase, identifying key structural features for their potency and safety in treating androgen-related conditions.

Validated method reliably measures finasteride in tablets using liquid chromatography.

This study found that among eleven tested polymethoxyflavones, 5-hydroxy-7,4′-dimethoxyflavone was the strongest steroid 5α-reductase inhibitor and suggests potential use for benign prostatic hyperplasia treatment.

Finasteride safely treats enlarged prostate and male-pattern baldness.

This review discusses the role of androgens in male sexual differentiation and characteristics and reports no new clinical results; it emphasizes the androgen dependence of male pattern scalp hair loss.

This study developed and validated a precise RP-HPLC-PDA method for estimating finasteride in bulk and tablet forms, suitable for quality control use.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This study developed a validated HPLC method for accurately estimating dutasteride and its related compounds in capsules, suitable for routine and stability sample analysis.

This study found that dutasteride is more cost-effective compared to finasteride for treating benign prostatic hyperplasia in Montenegro, justifying its funding by the national health insurance fund.

This study identified potent dual inhibitors of 5α-reductases 1 and 2 that may aid in designing new drugs for related diseases.

The Dawn spacecraft found that Ceres has complex organic molecules and a lot of water ice, hinting it might support life.

This review summarizes recent advancements in steroidal 5α-reductase inhibitors for benign prostatic hyperplasia and reports no new clinical results.